DOI: 10.1002/mrdd.20007. Psychopharmacology in fragile X syndrome

Psychopharmacology in fragile X syndrome—Present and future

10.1002/mrdd.20007

Crossref journal-article

Wiley

Mental Retardation and Developmental Disabilities Research Reviews (311)

Abstract

AbstractIn addition to cognitive disability, fragile X syndrome (FXS) is associated with behavioral problems that are often functionally limiting. There are few controlled trials to guide treatment; however, available information does suggest that medications can be quite helpful for a number of categories of behavioral disturbance in FXS. Specifically, stimulants appear to be quite useful for management of distractibility, hyperactivity, and impulsive behavior; antidepressants help with anxiety, obsessive‐compulsive behaviors and mood dysregulation; and antipsychotics can reduce aggression. These medications are supportive and help minimize dysfunctional behaviors and maximize functioning. As more is learned about the neural functions of FMRP, medications in the future will be expected to target specific synaptic mechanisms dysregulated in FXS brain and thus ameliorate the cognitive deficit with resultant behavioral improvements. This article summarizes knowledge about effectiveness and approaches to management of currently available psychopharmacology for behavior in FXS and discusses early leads to future treatments for cognition. MRDD Research Reviews 2004;10:42–48. © 2004 Wiley‐Liss, Inc.

Bibliography

BerryâKravis, E., & Potanos, K. (2004). Psychopharmacology in fragile X syndromeâPresent and future. Mental Retardation and Developmental Disabilities Research Reviews, 10(1), 42â48. Portico.

Authors 2

Elizabeth Berry‐Kravis (first)
Kristina Potanos (additional)

References 45 Referenced 119

10.1352/0047-6765(2001)039<0259:DBPCTO>2.0.CO;2
10.1097/00004583-199103000-00013
{'key': 'e_1_2_1_4_1', 'first-page': '89', 'article-title': 'Medication use in fragile X syndrome', 'volume': '4', 'author': 'Amaria RN', 'year': '2001', 'journal-title': 'Mental Health Asp Dev Dis'} / Mental Health Asp Dev Dis / Medication use in fragile X syndrome by Amaria RN (2001)
10.1124/jpet.102.040360
10.1111/j.1469-8749.2002.tb00277.x
10.1054/cupe.2002.0305
{'issue': '1', 'key': 'e_1_2_1_8_1', 'first-page': 'S65', 'article-title': 'L‐acetylcarnitine treatment on fragile X patient hyperactive behaviour', 'author': 'Calvani M', 'year': '2001', 'journal-title': 'Rev Neurol'} / Rev Neurol / L‐acetylcarnitine treatment on fragile X patient hyperactive behaviour by Calvani M (2001)
{'key': 'e_1_2_1_9_1', 'first-page': '398', 'article-title': 'Effects of long‐acting propanolol on agonistic and steriotyped behaviors in a man with pervasive developmental disorder and fragile X syndrome: A double‐blind placebo‐controlled study', 'volume': '11', 'author': 'Cohen IL', 'year': '1991', 'journal-title': 'J Clin Psychopharmacol'} / J Clin Psychopharmacol / Effects of long‐acting propanolol on agonistic and steriotyped behaviors in a man with pervasive developmental disorder and fragile X syndrome: A double‐blind placebo‐controlled study by Cohen IL (1991)
CohenJ KerrK IaconoT et al.2002.Measuring emotion behavior change and speech in individuals with fragile X syndrome whilst taking sertraline: A pilot of tools. Procedings of the 8thInternational Fragile X Conference Chicago.
10.1097/00004583-199207000-00024
10.1002/(SICI)1098-2396(199604)22:4<332::AID-SYN4>3.0.CO;2-C
10.1073/pnas.141145998
10.1097/00004714-200110000-00005
10.1002/ajmg.1320230119
10.1002/ajmg.1320300138
{'key': 'e_1_2_1_17_1', 'first-page': '155', 'article-title': 'Fluoxetine therapy in fragile X syndrome', 'volume': '7', 'author': 'Hagerman RJ', 'year': '1994', 'journal-title': 'Dev Brain Dys'} / Dev Brain Dys / Fluoxetine therapy in fragile X syndrome by Hagerman RJ (1994)
{'key': 'e_1_2_1_18_1', 'first-page': '336', 'article-title': 'A survey of the efficacy of clonidine in fragile X syndrome', 'volume': '8', 'author': 'Hagerman RJ', 'year': '1995', 'journal-title': 'Dev Brain Dys'} / Dev Brain Dys / A survey of the efficacy of clonidine in fragile X syndrome by Hagerman RJ (1995)
10.1002/(SICI)1096-8628(19990402)83:4<313::AID-AJMG15>3.0.CO;2-F
10.1002/jemt.10067
10.1523/JNEUROSCI.18-07-02740.1998 / J Neurosci / Facilitative effects of the ampakine CX516 on short term memory in rats: enhancement of delayed‐nonmatch‐to‐sample performance by Hampson RE (1998)
10.1023/A:1025760302598
10.1097/00004583-199109000-00021
10.1073/pnas.122205699
10.1006/exnr.1997.6581
10.1016/S0006-8993(96)01049-9
LauterbornJC BaudryM GallCM.2002.Ampakines increase BDNF expression in FMR1 knockout mice despite lower glutamate receptor levels. Procedings of the 8thInternational Fragile X Conference Chicago.
10.1006/mcne.2001.1085
10.1016/S0166-2236(00)01959-7
10.1006/exnr.1997.6447
10.1038/nn935
10.1146/annurev.neuro.25.112701.142758
10.1056/NEJMoa013171
10.1001/archpsyc.1996.01830110037005
10.1111/j.1528-1157.1999.tb00824.x
10.1111/j.1527-3458.2002.tb00228.x
{'key': 'e_1_2_1_37_1', 'first-page': '159', 'article-title': 'Buspirone treatment of aggression and anxiety in mentally retarded patients: A multiple‐baseline placebo lead‐in study', 'volume': '52', 'author': 'Ratey J', 'year': '1991', 'journal-title': 'J Clin Psychiatry'} / J Clin Psychiatry / Buspirone treatment of aggression and anxiety in mentally retarded patients: A multiple‐baseline placebo lead‐in study by Ratey J (1991)
RobertsJE BaileyDB BocciaML.2002.Psychophysiological measures of arousal: documentation of treatment effects and impact of disability. Proceedings of the 8thInternational Fragile X Conference Chicago.
10.1523/JNEUROSCI.17-15-05928.1997 / J Neurosci / AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired by Rogan MT (1997)
10.1038/nn746
10.1073/pnas.91.2.777
10.1002/ajmg.1320440529
10.1002/(SICI)1096-8628(19991203)87:4<366::AID-AJMG18>3.0.CO;2-F
10.1046/j.1365-2788.1996.806806.x
10.1016/S0092-8674(03)00079-5
10.1097/00004714-199210000-00010

Dates

Type	When
Created	21 years, 6 months ago (Feb. 26, 2004, 3:20 p.m.)
Deposited	1 year, 11 months ago (Sept. 12, 2023, 6:06 a.m.)
Indexed	4 months, 3 weeks ago (April 11, 2025, 7:26 a.m.)
Issued	21 years, 7 months ago (Feb. 1, 2004)
Published	21 years, 7 months ago (Feb. 1, 2004)
Published Online	21 years, 6 months ago (Feb. 17, 2004)
Published Print	21 years, 7 months ago (Feb. 1, 2004)

Funders 0

None

BibTeX

@article{Berry_Kravis_2004, title={Psychopharmacology in fragile X syndrome—Present and future}, volume={10}, ISSN={1098-2779}, url={http://dx.doi.org/10.1002/mrdd.20007}, DOI={10.1002/mrdd.20007}, number={1}, journal={Mental Retardation and Developmental Disabilities Research Reviews}, publisher={Wiley}, author={Berry‐Kravis, Elizabeth and Potanos, Kristina}, year={2004}, month=feb, pages={42–48} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        4,
        11
      ]
    ],
    "date-time": "2025-04-11T11:26:03Z",
    "timestamp": 1744370763152
  },
  "reference-count": 45,
  "publisher": "Wiley",
  "issue": "1",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2004,
            2,
            17
          ]
        ],
        "date-time": "2004-02-17T00:00:00Z",
        "timestamp": 1076976000000
      },
      "content-version": "vor",
      "delay-in-days": 16,
      "URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor"
    }
  ],
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2004,
        2
      ]
    ]
  },
  "abstract": "<jats:title>Abstract</jats:title><jats:p>In addition to cognitive disability, fragile X syndrome (FXS) is associated with behavioral problems that are often functionally limiting. There are few controlled trials to guide treatment; however, available information does suggest that medications can be quite helpful for a number of categories of behavioral disturbance in FXS. Specifically, stimulants appear to be quite useful for management of distractibility, hyperactivity, and impulsive behavior; antidepressants help with anxiety, obsessive\u2010compulsive behaviors and mood dysregulation; and antipsychotics can reduce aggression. These medications are supportive and help minimize dysfunctional behaviors and maximize functioning. As more is learned about the neural functions of FMRP, medications in the future will be expected to target specific synaptic mechanisms dysregulated in FXS brain and thus ameliorate the cognitive deficit with resultant behavioral improvements. This article summarizes knowledge about effectiveness and approaches to management of currently available psychopharmacology for behavior in FXS and discusses early leads to future treatments for cognition. MRDD Research Reviews 2004;10:42\u201348. \u00a9 2004 Wiley\u2010Liss, Inc.</jats:p>",
  "DOI": "10.1002/mrdd.20007",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2004,
        2,
        26
      ]
    ],
    "date-time": "2004-02-26T20:20:53Z",
    "timestamp": 1077826853000
  },
  "page": "42-48",
  "source": "Crossref",
  "is-referenced-by-count": 119,
  "title": "Psychopharmacology in fragile X syndrome\u2014Present and future",
  "prefix": "10.1002",
  "volume": "10",
  "author": [
    {
      "given": "Elizabeth",
      "family": "Berry\u2010Kravis",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "Kristina",
      "family": "Potanos",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "311",
  "published-online": {
    "date-parts": [
      [
        2004,
        2,
        17
      ]
    ]
  },
  "reference": [
    {
      "key": "e_1_2_1_2_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1352/0047-6765(2001)039<0259:DBPCTO>2.0.CO;2"
    },
    {
      "key": "e_1_2_1_3_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1097/00004583-199103000-00013"
    },
    {
      "key": "e_1_2_1_4_1",
      "first-page": "89",
      "article-title": "Medication use in fragile X syndrome",
      "volume": "4",
      "author": "Amaria RN",
      "year": "2001",
      "journal-title": "Mental Health Asp Dev Dis"
    },
    {
      "key": "e_1_2_1_5_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1124/jpet.102.040360"
    },
    {
      "key": "e_1_2_1_6_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1111/j.1469-8749.2002.tb00277.x"
    },
    {
      "key": "e_1_2_1_7_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1054/cupe.2002.0305"
    },
    {
      "issue": "1",
      "key": "e_1_2_1_8_1",
      "first-page": "S65",
      "article-title": "L\u2010acetylcarnitine treatment on fragile X patient hyperactive behaviour",
      "author": "Calvani M",
      "year": "2001",
      "journal-title": "Rev Neurol"
    },
    {
      "key": "e_1_2_1_9_1",
      "first-page": "398",
      "article-title": "Effects of long\u2010acting propanolol on agonistic and steriotyped behaviors in a man with pervasive developmental disorder and fragile X syndrome: A double\u2010blind placebo\u2010controlled study",
      "volume": "11",
      "author": "Cohen IL",
      "year": "1991",
      "journal-title": "J Clin Psychopharmacol"
    },
    {
      "key": "e_1_2_1_10_1",
      "unstructured": "CohenJ KerrK IaconoT et al.2002.Measuring emotion behavior change and speech in individuals with fragile X syndrome whilst taking sertraline: A pilot of tools. Procedings of the 8thInternational Fragile X Conference Chicago."
    },
    {
      "key": "e_1_2_1_11_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1097/00004583-199207000-00024"
    },
    {
      "key": "e_1_2_1_12_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1002/(SICI)1098-2396(199604)22:4<332::AID-SYN4>3.0.CO;2-C"
    },
    {
      "key": "e_1_2_1_13_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1073/pnas.141145998"
    },
    {
      "key": "e_1_2_1_14_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1097/00004714-200110000-00005"
    },
    {
      "key": "e_1_2_1_15_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1002/ajmg.1320230119"
    },
    {
      "key": "e_1_2_1_16_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1002/ajmg.1320300138"
    },
    {
      "key": "e_1_2_1_17_1",
      "first-page": "155",
      "article-title": "Fluoxetine therapy in fragile X syndrome",
      "volume": "7",
      "author": "Hagerman RJ",
      "year": "1994",
      "journal-title": "Dev Brain Dys"
    },
    {
      "key": "e_1_2_1_18_1",
      "first-page": "336",
      "article-title": "A survey of the efficacy of clonidine in fragile X syndrome",
      "volume": "8",
      "author": "Hagerman RJ",
      "year": "1995",
      "journal-title": "Dev Brain Dys"
    },
    {
      "key": "e_1_2_1_19_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1002/(SICI)1096-8628(19990402)83:4<313::AID-AJMG15>3.0.CO;2-F"
    },
    {
      "key": "e_1_2_1_20_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1002/jemt.10067"
    },
    {
      "key": "e_1_2_1_21_1",
      "doi-asserted-by": "crossref",
      "first-page": "2740",
      "DOI": "10.1523/JNEUROSCI.18-07-02740.1998",
      "article-title": "Facilitative effects of the ampakine CX516 on short term memory in rats: enhancement of delayed\u2010nonmatch\u2010to\u2010sample performance",
      "volume": "18",
      "author": "Hampson RE",
      "year": "1998",
      "journal-title": "J Neurosci"
    },
    {
      "key": "e_1_2_1_22_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1023/A:1025760302598"
    },
    {
      "key": "e_1_2_1_23_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1097/00004583-199109000-00021"
    },
    {
      "key": "e_1_2_1_24_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1073/pnas.122205699"
    },
    {
      "key": "e_1_2_1_25_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1006/exnr.1997.6581"
    },
    {
      "key": "e_1_2_1_26_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0006-8993(96)01049-9"
    },
    {
      "key": "e_1_2_1_27_1",
      "unstructured": "LauterbornJC BaudryM GallCM.2002.Ampakines increase BDNF expression in FMR1 knockout mice despite lower glutamate receptor levels. Procedings of the 8thInternational Fragile X Conference Chicago."
    },
    {
      "key": "e_1_2_1_28_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1006/mcne.2001.1085"
    },
    {
      "key": "e_1_2_1_29_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0166-2236(00)01959-7"
    },
    {
      "key": "e_1_2_1_30_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1006/exnr.1997.6447"
    },
    {
      "key": "e_1_2_1_31_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1038/nn935"
    },
    {
      "key": "e_1_2_1_32_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1146/annurev.neuro.25.112701.142758"
    },
    {
      "key": "e_1_2_1_33_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1056/NEJMoa013171"
    },
    {
      "key": "e_1_2_1_34_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1001/archpsyc.1996.01830110037005"
    },
    {
      "key": "e_1_2_1_35_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1111/j.1528-1157.1999.tb00824.x"
    },
    {
      "key": "e_1_2_1_36_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1111/j.1527-3458.2002.tb00228.x"
    },
    {
      "key": "e_1_2_1_37_1",
      "first-page": "159",
      "article-title": "Buspirone treatment of aggression and anxiety in mentally retarded patients: A multiple\u2010baseline placebo lead\u2010in study",
      "volume": "52",
      "author": "Ratey J",
      "year": "1991",
      "journal-title": "J Clin Psychiatry"
    },
    {
      "key": "e_1_2_1_38_1",
      "unstructured": "RobertsJE BaileyDB BocciaML.2002.Psychophysiological measures of arousal: documentation of treatment effects and impact of disability. Proceedings of the 8thInternational Fragile X Conference Chicago."
    },
    {
      "key": "e_1_2_1_39_1",
      "doi-asserted-by": "crossref",
      "first-page": "5928",
      "DOI": "10.1523/JNEUROSCI.17-15-05928.1997",
      "article-title": "AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired",
      "volume": "17",
      "author": "Rogan MT",
      "year": "1997",
      "journal-title": "J Neurosci"
    },
    {
      "key": "e_1_2_1_40_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1038/nn746"
    },
    {
      "key": "e_1_2_1_41_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1073/pnas.91.2.777"
    },
    {
      "key": "e_1_2_1_42_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1002/ajmg.1320440529"
    },
    {
      "key": "e_1_2_1_43_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1002/(SICI)1096-8628(19991203)87:4<366::AID-AJMG18>3.0.CO;2-F"
    },
    {
      "key": "e_1_2_1_44_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1046/j.1365-2788.1996.806806.x"
    },
    {
      "key": "e_1_2_1_45_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0092-8674(03)00079-5"
    },
    {
      "key": "e_1_2_1_46_1",
      "doi-asserted-by": "publisher",
      "DOI": "10.1097/00004714-199210000-00010"
    }
  ],
  "container-title": "Mental Retardation and Developmental Disabilities Research Reviews",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fmrdd.20007",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/mrdd.20007",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2023,
        9,
        12
      ]
    ],
    "date-time": "2023-09-12T10:06:34Z",
    "timestamp": 1694513194000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://onlinelibrary.wiley.com/doi/10.1002/mrdd.20007"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2004,
        2
      ]
    ]
  },
  "references-count": 45,
  "journal-issue": {
    "issue": "1",
    "published-print": {
      "date-parts": [
        [
          2004,
          2
        ]
      ]
    }
  },
  "alternative-id": [
    "10.1002/mrdd.20007"
  ],
  "URL": "http://dx.doi.org/10.1002/mrdd.20007",
  "relation": {},
  "ISSN": [
    "1080-4013",
    "1098-2779"
  ],
  "subject": [],
  "container-title-short": "Ment. Retard. Dev. Disabil. Res. Rev.",
  "published": {
    "date-parts": [
      [
        2004,
        2
      ]
    ]
  }
}